This decision followed a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency on May 21 and is applicable for all member states in the European Union.

"We are delighted to offer a novel, non-invasive treatment option for women suffering of debilitating symptoms of uterine fibroids," said Erik Bogsch, chairman of Gedeon Richter Plc. "Richter strives to exploit additional therapeutic advantages promised by RYEQO® and remains committed to further expand its women’s healthcare portfolio in order to improve overall quality of life for female population."